"Ypsomed Sells Ypsotec AG to Callista Asset Management to Focus on Core Medical Technology Solutions"

"Ypsomed has sold its subsidiary, Ypsotec AG, to Callista Asset Management 32 GmbH as part of its strategic focus on core medical technology solutions for self-injection. The sale, completed on October 31, 2025, allows Ypsomed to invest further in innovative therapeutic solutions. Ypsomed, headquartered in Switzerland, is a leading developer of injection systems for self-administration of medicines, supporting improved therapy and quality of life for people with chronic diseases. Legal advice for the transaction was provided by CMS."

CMS Switzerland and CMS Czech Republic advised Ypsomed Holding AG on the sale of Ypsotec AG to Callista Asset Management 32 GmbH. The transaction, completed on October 31, 2025, involved the sale of all shares in Ypsotec AG, which operates in Switzerland and the Czech Republic. This strategic move allows Ypsomed to focus on its core competencies in medical technology solutions for self-injection and to invest further in innovative therapeutic solutions. Callista Asset Management 32 GmbH, an entrepreneurial investor specializing in transforming industrial companies, acquired Ypsotec AG. The CMS team advising Ypsomed Holding AG included Stefan Brunnschweiler (Partner, Corporate/M&A), Florian Jung (Senior Associate, Corporate/M&A), Raphael Hammer (Attorney Trainee, Corporate/M&A), Marquard Christen (Partner, Competition Law), Julia Haas (Senior Associate, Competition Law), Kaspar Landolt (Partner, Banking & Finance), and Mark Cagienard (Partner, Tax Law) from CMS Switzerland, as well as Helen Rodwell (Partner) and Lucia Luptakova (Senior Associate) from CMS Czech Republic.

"Ypsomed Sells Ypsotec AG to Callista Asset Management to Focus on Core Medical Technology Solutions"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads